EUVIMEDEUVIMED entdecken
Crossref

Medical Cannabis Legalization: No Contribution to Rising Stimulant Rates in the USA

Garrett D Alexander, Luke R Cavanah, Jessica L Goldhirsh, Leighton Y Huey, Brian J Piper

Pharmacopsychiatry · 01.11.2023 · 56 (06) · 214-218

DOI: 10.1055/a-2152-7757 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmacopsychiatry, erschienen am 01.11.2023. Verfasst von Garrett D Alexander und 4 weiteren Autor:innen. Beteiligte Einrichtung: Geisinger Commonwealth School of Medicine, Scranton, PA, United States. Hauptthemen laut MEDLINE: Medical Marijuana, Central Nervous System Stimulants, Methylphenidate, Attention Deficit Disorder with Hyperactivity. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 26 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

There has been a pronounced increase in the use of Schedule II stimulants to treat attention-deficit hyperactivity disorder (ADHD) in the United States over the last two decades. Interestingly, chronic medical cannabis (MC) use can present with cognitive impairments that resemble ADHD symptoms. This study aimed to determine if MC legalization increased prescription stimulant distribution.

Methods

Information on the distribution of methylphenidate, amphetamine, and lisdexamfetamine for 2006 to 2021 was extracted from the Drug Enforcement Administration’s comprehensive database and the three-year population-corrected slopes of stimulant distribution before and after MC program implementation were compared.

Results

We found a significant main effect of time (p

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Medical MarijuanaCentral Nervous System StimulantsMethylphenidateAttention Deficit Disorder with HyperactivityAdultHumansUnited StatesAmphetamine

Substanzen

Medical MarijuanaCentral Nervous System StimulantsMethylphenidateAmphetamine

Autor:innen und Institutionen

  • Geisinger Commonwealth School of Medicine, Scranton, PA, United States.
  • Behavioral Health Initiative, Scranton, PA, United States.
  • Center for Pharmacy Innovation and Outcomes, Forty Fort, PA, United States.

Zitieren

APA

Alexander, G. D., Cavanah, L. R., Goldhirsh, J. L., Huey, L. Y., & Piper, B. J. (2023). Medical Cannabis Legalization: No Contribution to Rising Stimulant Rates in the USA. Pharmacopsychiatry, 56(06), 214-218. https://doi.org/10.1055/a-2152-7757

Vancouver

Alexander GD, Cavanah LR, Goldhirsh JL, Huey LY, Piper BJ. Medical Cannabis Legalization: No Contribution to Rising Stimulant Rates in the USA. Pharmacopsychiatry. 2023;56(06):214-218. doi:10.1055/a-2152-7757

BibTeX
@article{Alexander2023,
  author = {Alexander, Garrett D and Cavanah, Luke R and Goldhirsh, Jessica L and Huey, Leighton Y and Piper, Brian J},
  title = {Medical Cannabis Legalization: No Contribution to Rising Stimulant Rates in the USA},
  journal = {Pharmacopsychiatry},
  year = {2023},
  volume = {56},
  number = {06},
  pages = {214--218},
  doi = {10.1055/a-2152-7757}
}
Kostenlos starten →